Genoks plans to leverage Velsera’s capabilities to enhance its oncology diagnostics capabilities in Turkey. Credit: Juan Ci / Shutterstock.

Genoks and healthcare technology company Velsera have partnered to enhance diagnostics and treatment for cancer in Turkey and surrounding regions.

The collaboration will integrate Velsera’s Clinical Genomics Workspace (CGW) with Genoks’s knowledge in genomics to improve the detection and characterisation of various cancer types.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The CGW platform from Velsera is designed for comprehensive analysis of data from solid tissue, liquid tumours, and haematological cancer samples.

It is tailored for oncology and inherited disease specialists, facilitating the growth of next-generation sequencing (NGS) testing programmes.

Genoks plans to leverage Velsera’s capabilities in data interpretation and genomic analysis to enhance its oncology diagnostics capabilities in Turkey.

See Also:

By adopting Velsera’s advanced algorithms and tools, Genoks aims to provide precise and personalised testing solutions. This will enable healthcare providers to offer targeted treatments based on each patient’s genetic profile.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The partnership is expected to advance Genoks’ position in oncology diagnostics in the country.

The collaboration between Genoks and Velsera highlights the importance of strategic partnerships in driving forward cancer research and improving patient outcomes.

Genoks clinical geneticist Dr Yunus Alp said: “We are thrilled to partner with Velsera in our shared mission to revolutionise cancer diagnostics and treatment in Turkey and beyond.

“Together, we are poised to make a significant impact in the fight against cancer, empowering clinicians with precise insights to guide treatment decisions and improve patient outcomes.”